A number of GLP-1 analogs are being developed as pharmaceutical agents for the treatment of type-2 diabetes, as GLP-1 increases postprandial insulin secretion, suppresses postprandial glucagon secretion, and delays gastric emptying (120). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.